Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 362

Document Document Title
WO/2018/197663A1
A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.  
WO/2018/178226A1
Disclosed are Mcl-1 inhibitors, pharmaceutical compositions comprising the same and methods of using the same.  
WO/2018/153326A1
The present invention relates to a sulfonyl hydrazine compound and a use thereof as a medicament for use in treating hepatitis B. Specifically, the present invention discloses a compound which may act as an HBV inhibitor and which has th...  
WO/2018/108070A1
A compound comprises a donor and an acceptor, wherein at least one donor ( "D" ) and at least one acceptor ( "A" ) may be arranged in an order of D-A; D-A-D; A-D-A; D-D-A-D-D; A-A-D-A-A; D-A-D-A-D; and A-D-A-D-A. The compound may be sele...  
WO/2018/109643A1
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula...  
WO/2017/202340A1
Disclosed are a series of photoisomeric compounds, preparation method therefor and devices comprising the compounds, wherein a photoisomeric compound-graphene molecular junction device is formed by linking the photoisomeric compound to a...  
WO/2017/182625A1
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13 ,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030, 35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-ca rbo...  
WO/2017/147410A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharma...  
WO/2017/127820A1
Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria. In at least one specific embodiment, the compounds or salts thereof can include compounds of Formula (I):  
WO/2017/105040A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...  
WO/2017/060167A1
The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular o...  
WO/2017/021805A1
The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salt...  
WO/2017/001655A1
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...  
WO/2016/130818A1
The present invention relates to compounds according to Formula (I-l) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  
WO/2016/071499A1
The present invention relates to the use of substituted 3-pyridyl heterobicyclic compounds of formula I as agrochemical pesticides. Furthermore, the present invention relates to novel substituted 3-pyridylheterobicyclic compounds of form...  
WO/2016/067009A1
This invention relates toantibacterial drug compounds containing a tricyclic ring system and pharmaceutical formulations thereof. The compounds are useful in the treatment of bacterial and mycobacterial infections, and particularly tuber...  
WO/2015/123230A1
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions cont...  
WO/2015/061426A1
Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N 6 -[(3-halothien-2-yl)methyl]adenosine, N 6 -[...  
WO/2015/050989A3
The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative d...  
WO/2015/038661A1
Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositi...  
WO/2015/027214A1
In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6- carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine rec...  
WO/2015/027204A1
In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (...  
WO/2014/164428A1
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions contai...  
WO/2014/152275A1
This invention relates to novel NS5B polymerase inhibitors and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of tr...  
WO/2014/140299A1
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatm...  
WO/2014/140313A1
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, f...  
WO/2014/092100A1
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...  
WO/2014/043272A1
Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricycli...  
WO/2013/148537A1
The present invention provides spirobicyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, diff...  
WO/2013/139697A1
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...  
WO/2013/104613A1
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2013/046029A1
The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention prov...  
WO/2013/033245A1
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...  
WO/2013/016441A1
Novel oxoisoindoline sulfonamide integrase inhibitors are useful to inhibit HIV activity, and are therefore suitable for treatment or prophylaxis of HIV infection, for example in the treatment or prevention of AIDS. In particular embodim...  
WO/2012/158933A3
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.  
WO/2012/158933A9
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.  
WO/2012/120056A1
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.  
WO/2012/120052A1
The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.  
WO/2012/112345A1
This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection o...  
WO/2012/075048A2
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially sp...  
WO/2012/075048A3
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially sp...  
WO/2012/012391A3
The present invention relates to a process comprising the step of dehydrating a compound of Formula (I): with a suitable dehydrating reagent to form a compound of Formula (II): wherein R1-R7 as defined herein. Compounds of Formula (II) h...  
WO/2012/009001A3
The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the tre...  
WO/2012/006760A1
The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bon...  
WO/2011/151348A1
This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compos...  
WO/2011/147828A1
This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ectainascidins of formula I from compounds of formula II, and to processes for the synthesis of compo...  
WO/2011/121105A1
Compound having Formula (I) and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.  
WO/2011/116336A1
Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof:(I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorde...  
WO/2011/095057A1
Benzimidazole derivatives and pharmaceutical compositions and use thereof are disclosed. Benzimidazole derivatives represented by general formula (I) or their stereoisomers, pharmaceutically acceptable compositions and solvates thereof a...  
WO/2011/045330A1
Compound having formula (I), wherein - W is NH-, -N(CH3)- or piperazine, - X is a bond, -C(=O)- or S(=O)2-, - Y is C3-7alkylene, and - Z is NH-C(=O)- or -O-, and pharmaceutically acceptable salts thereof, their pharmaceutical formulation...  

Matches 1 - 50 out of 362